The company, founded in 2016 and based in Cleveland, Ohio, develops a technology platform that combines CellPrint, an analytical modality, with CellMed, an approach for discovering biomarkers and drug targets. Their focus is on multiple sclerosis and cancer therapeutic areas, providing high-resolution molecular expression analysis of cells in peripheral blood. This platform enables ultra-sensitive detection and precise quantification of molecular expression, leading to insights about pathogenesis and potential therapeutic interventions.